

Epilepsy Patients Set To Benefit From Non-Invasive, Real-Time Molecular Breath Analysis

ST NEOTS, UK, August 24, 2022

/EINPresswire.com/ -- Deep Breath Intelligence is pleased to announce the launch of DBI-EPIbreath®, a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication (ASM) valproic acid to aid patient

management. This innovative diagnostics tool will be showcased at the European Epilepsy Congress taking place in Geneva, Switzerland, from the 9th to the 13th of July.



Fast diagnosis and quick medication decisions are essential for epileptic seizure control. Standard therapeutic drug monitoring (TDM) approaches are based on measuring drug concentrations in plasma or serum, but this has limitations, and it can take several days to turn around results. DBI-EPIbreath® is the first CE-IVDD certified, non-invasive test that allows real-time measurement of the total and free concentrations of valproic acid in a breath sample, delivering results in just 10 minutes. The test combines secondary electrospray ionization-high resolution mass spectrometry (SESI-HRMS) with sophisticated bioinformatic tools to assist in the management of ASM dosing regimens. Patients simply exhale into a SESI-HRMS instrument, and the data is analyzed using machine learning algorithms. DBI-EPIbreath® also predicts the likelihood – low, moderate or high – of drug response, as well as providing a side effects risk score, helping clinicians to identify whether a patient is likely to benefit from the treatment and/or suffer from unwanted side effects.

Tests can be performed as often as necessary, making the technique an ideal fast and non-invasive diagnostics tool to complement blood testing. It is particularly advantageous for pediatric patients – where blood draws can be challenging – or if more frequent testing is required for any reason, such as individuals who are non-responsive or develop pharmacoresistance. This machine learning approach has potential to be expanded to include other ASMs in the future, enabling many more people with epilepsy to benefit from fast, non-invasive TDM.

For more information, visit <https://dbi.ch>

About Deep Breath Intelligence

We rethink breath. Deep Breath Intelligence is a healthtech company unleashing the huge potential of analyzing exhaled breath by applying machine learning algorithms. We provide non-invasive solutions for early diagnosis of diseases and therapeutic drug monitoring – enabling better treatment by precision medicine. Our first product, DBI-EPIbreath®, is a CE-IVDD certified test for drug monitoring in epilepsy. We are working hard today on developing a broad range of products in different disease areas to take future precision medicine to the next level and improve people's health.

CONTACTS

Sarah Khan
ideas@kdm-communications.com
kdm communications limited
Phone: +44 1480 405333

Sarah Khan
kdm communications limited
+44 1480 405333
ideas@kdm-communications.com

This press release can be viewed online at: <https://www.einpresswire.com/article/587520433>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.